IMRNW (Immuron) Forward Dividend Yield %: 0.00% (As of Jul. 01, 2026)


What is Immuron Forward Dividend Yield %?

Immuron IMRNW Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. The stock has 4 warning signs investors should review. Among 147 Biotechnology companies, Immuron ranks worse than 680271.43% on this metric.

As of today (2026-07-01), the Forward Annual Dividend Yield of Immuron is 0.00%.

As of today (2026-07-01), the Trailing Annual Dividend Yield of Immuron is 0.00%.

IMRNW's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

Immuron's Dividends per Share for the six months ended in Dec. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Immuron  (NAS:IMRNW) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Immuron Forward Dividend Yield % Related Terms

IMRNW vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Immuron's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Immuron's Forward Dividend Yield % falls into.


Immuron Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Immuron (IMRNW) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Immuron and its competitors. According to the industry distribution chart, Immuron ranks #999999 out of 147 companies in the Biotechnology industry.
Is Immuron's Forward Dividend Yield % too high?
Immuron's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Immuron ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Immuron's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #999999 out of 147 companies for Forward Dividend Yield %. This places Immuron in the lower half of its industry. The industry median Forward Dividend Yield % is 1.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.45, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Immuron and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Immuron (IMRNW) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Immuron (IMRNW), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immuron Business Description

Address 25-37, Chapman Street, Unit 10, Blackburn, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.